Friday 6 November 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
313.98
12.31
−3.77%
Follow CRL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
281.96 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.55 | 2.72 | 2.10 | 2.46 | |
P/FCF ratio |
35.29 | 29.39 | 21.58 | 19.07 | |
P/Operating CF |
55.50 | 60.60 | 205.57 | 67.02 | |
P/B ratio |
4.36 | 3.83 | 2.87 | 3.12 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 150.53 | |
EV/Sales |
4.11 | 3.33 | 2.71 | 2.94 | |
EV/EBITDA |
29.56 | 24.09 | 18.65 | 19.90 | |
EV/Operating CF |
26.27 | 22.88 | 17.99 | 16.01 | |
EV/FCF |
40.91 | 35.94 | 27.90 | 22.78 | |
Quick Ratio |
0.86 | 0.80 | 0.82 | 0.82 | |
Current Ratio |
1.41 | 1.35 | 1.36 | 1.29 | |
Net Debt/EBITDA |
0.00 | 12.97 | 13.21 | (47.87) | |
Debt/Assets |
32.79% | 34.78% | 34.45% | 29.94% | |
Debt/Equity |
0.76 | 0.92 | 0.90 | 0.67 | |
Asset Turnover |
0.53 | 0.53 | 0.53 | 0.55 | |
Operating CF/Net income |
0.76 | (121.27) | (2.77) | (0.53) | |
Capex/Depreciation |
(0.65) | (0.46) | (0.83) | (0.37) | |
Interest Coverage |
7.10 | 3.95 | 4.48 | (11.92) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
14.31% | 22.80% | 16.01% | 19.73% | |
Intangible Assets out of Total Assets |
0.45 | 0.44 | 0.43 | 0.44 | |
Share Based Compensation of Revenue |
2.11% | 1.97% | 2.25% | 1.77% | |
Graham Net Nets |
(0.19) | (0.29) | (0.39) | (0.25) | |
Graham Number |
39.90 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.35% | (2.13%) | (2.17%) | (1.48%) | |
Free Cash Flow Yield |
2.83% | 3.40% | 4.63% | 5.24% | |
Revenue per Share |
20.56 | 20.91 | 20.34 | 20.06 | |
Operating CF per Share |
5.32 | 3.74 | 0.84 | 2.98 | |
Capex per Share |
(0.98) | (0.65) | (1.14) | (1.79) | |
Free Cash Flow per Share |
4.34 | 3.09 | (0.30) | 1.18 | |
Cash per Share |
4.19 | 4.00 | 3.92 | 4.31 | |
Shareholders Equity per Share |
67.61 | 59.27 | 60.19 | 63.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
67.61 | 59.27 | 60.19 | 63.96 | |
Free Cash Flow |
207.28 | 148.62 | (14.83) | 58.57 | |
Working Capital |
445.77 | 394.36 | 395.10 | 326.73 | |
Capital Expenditures |
(46.81) | (31.10) | (55.91) | (88.95) | |
Net Current Asset Value |
(2,684.39) | (3,157.05) | (3,295.09) | (2,518.44) | |
EV/EBIT |
102.83 | 147.77 | 155.10 | 469.42 | |
Capex to Sales |
0.05 | 0.03 | 0.06 | 0.09 | |
Price to Operating Income |
88.70 | 120.81 | 119.96 | 392.93 | |
| Other line items | |||||
Average Receivables |
734.89 | 739.66 | 728.44 | 714.89 | |
Average Payables |
157.06 | 143.39 | 141.64 | 144.57 | |
Average Inventory |
311.09 | 312.91 | 324.94 | 288.82 | |
Average Assets |
7,482.66 | 7,546.35 | 7,656.34 | 7,331.88 | |
Average Common Equity |
3,321.21 | 3,102.81 | 3,073.27 | 3,318.44 |
Columns are period end dates · fundamentals updated 5 Nov 2026